Impact of Oseltamivir and Diabetes Development
<b>Background/Objectives</b>: Influenza is a major global health challenge, causing thousands of deaths annually. Antiviral drugs, particularly oseltamivir, a neuraminidase inhibitor, have become essential therapeutic options due to their oral bioavailability and efficacy. Previous studi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587739340472320 |
|---|---|
| author | Bor-Show Tzang Chih-Chen Tzang Pei-Hua Chuang I-Ying Kuo Yu-Chun Pan Pei-Hsun Wu Tsai-Ching Hsu |
| author_facet | Bor-Show Tzang Chih-Chen Tzang Pei-Hua Chuang I-Ying Kuo Yu-Chun Pan Pei-Hsun Wu Tsai-Ching Hsu |
| author_sort | Bor-Show Tzang |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Influenza is a major global health challenge, causing thousands of deaths annually. Antiviral drugs, particularly oseltamivir, a neuraminidase inhibitor, have become essential therapeutic options due to their oral bioavailability and efficacy. Previous studies suggest a potential association between oseltamivir use and the onset of diabetes mellitus. However, further investigation is needed to establish a definitive link. <b>Methods</b>: This retrospective cohort study utilized data from the Taiwan National Health Insurance Research Database (NHIRD), including 1,631,968 patients (815,984 oseltamivir users) between 1 January 2009 and 28 December 2018. All statistical analyses were performed using SAS 9.4M8 software (SAS Institute Inc., Cary, NC, USA). <b>Results</b>: Cox proportional hazards regression and multivariate analyses revealed a statistically significant association between oseltamivir use and overall diabetes risk (HR = 1.027, <i>p</i> = 0.0186). While no significant association was observed for Type 1 diabetes (HR = 1.021; <i>p</i> = 0.06795), oseltamivir users showed a higher incidence of Type 2 diabetes (HR = 1.024; <i>p</i> < 0.05). Oseltamivir was also linked to increased risks of comorbidities, including dyslipidemia (HR = 1.295, <i>p</i> < 0.0001), chronic liver disease (HR = 1.446, <i>p</i> < 0.0001), hypertension (HR = 1.586, <i>p</i> < 0.0001), and obesity (HR = 2.949, <i>p</i> < 0.0001). <b>Conclusions</b>: Oseltamivir is associated with an increased risk of Type 2 diabetes but not Type 1, and related comorbidities. |
| format | Article |
| id | doaj-art-c9c2400b1d504c749d28e80d0f2d2bd6 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-c9c2400b1d504c749d28e80d0f2d2bd62025-01-24T13:45:29ZengMDPI AGPharmaceuticals1424-82472025-01-0118112810.3390/ph18010128Impact of Oseltamivir and Diabetes DevelopmentBor-Show Tzang0Chih-Chen Tzang1Pei-Hua Chuang2I-Ying Kuo3Yu-Chun Pan4Pei-Hsun Wu5Tsai-Ching Hsu6Department of Biochemistry, School of Medicine, Chung Shan Medical University, Taichung 402, TaiwanSchool of Medicine, College of Medicine, National Taiwan University, Taipei City 100, TaiwanInstitute of Medicine, Chung Shan Medical University, Taichung 402, TaiwanDepartment of Biotechnology, College of Biomedical Science, Kaohsiung Medical University, Kaohsiung 807, TaiwanSchool of Medicine, College of Medicine, National Taiwan University, Taipei City 100, TaiwanSchool of Medicine, College of Medicine, National Taiwan University, Taipei City 100, TaiwanInstitute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan<b>Background/Objectives</b>: Influenza is a major global health challenge, causing thousands of deaths annually. Antiviral drugs, particularly oseltamivir, a neuraminidase inhibitor, have become essential therapeutic options due to their oral bioavailability and efficacy. Previous studies suggest a potential association between oseltamivir use and the onset of diabetes mellitus. However, further investigation is needed to establish a definitive link. <b>Methods</b>: This retrospective cohort study utilized data from the Taiwan National Health Insurance Research Database (NHIRD), including 1,631,968 patients (815,984 oseltamivir users) between 1 January 2009 and 28 December 2018. All statistical analyses were performed using SAS 9.4M8 software (SAS Institute Inc., Cary, NC, USA). <b>Results</b>: Cox proportional hazards regression and multivariate analyses revealed a statistically significant association between oseltamivir use and overall diabetes risk (HR = 1.027, <i>p</i> = 0.0186). While no significant association was observed for Type 1 diabetes (HR = 1.021; <i>p</i> = 0.06795), oseltamivir users showed a higher incidence of Type 2 diabetes (HR = 1.024; <i>p</i> < 0.05). Oseltamivir was also linked to increased risks of comorbidities, including dyslipidemia (HR = 1.295, <i>p</i> < 0.0001), chronic liver disease (HR = 1.446, <i>p</i> < 0.0001), hypertension (HR = 1.586, <i>p</i> < 0.0001), and obesity (HR = 2.949, <i>p</i> < 0.0001). <b>Conclusions</b>: Oseltamivir is associated with an increased risk of Type 2 diabetes but not Type 1, and related comorbidities.https://www.mdpi.com/1424-8247/18/1/128antiviral therapyneuraminidase inhibitorsretrospective cohort studyTaiwan National Health Insurance Research Database |
| spellingShingle | Bor-Show Tzang Chih-Chen Tzang Pei-Hua Chuang I-Ying Kuo Yu-Chun Pan Pei-Hsun Wu Tsai-Ching Hsu Impact of Oseltamivir and Diabetes Development Pharmaceuticals antiviral therapy neuraminidase inhibitors retrospective cohort study Taiwan National Health Insurance Research Database |
| title | Impact of Oseltamivir and Diabetes Development |
| title_full | Impact of Oseltamivir and Diabetes Development |
| title_fullStr | Impact of Oseltamivir and Diabetes Development |
| title_full_unstemmed | Impact of Oseltamivir and Diabetes Development |
| title_short | Impact of Oseltamivir and Diabetes Development |
| title_sort | impact of oseltamivir and diabetes development |
| topic | antiviral therapy neuraminidase inhibitors retrospective cohort study Taiwan National Health Insurance Research Database |
| url | https://www.mdpi.com/1424-8247/18/1/128 |
| work_keys_str_mv | AT borshowtzang impactofoseltamiviranddiabetesdevelopment AT chihchentzang impactofoseltamiviranddiabetesdevelopment AT peihuachuang impactofoseltamiviranddiabetesdevelopment AT iyingkuo impactofoseltamiviranddiabetesdevelopment AT yuchunpan impactofoseltamiviranddiabetesdevelopment AT peihsunwu impactofoseltamiviranddiabetesdevelopment AT tsaichinghsu impactofoseltamiviranddiabetesdevelopment |